Guido Marcucci

Summary

Affiliation: The Ohio State University
Country: USA

Publications

  1. ncbi request reprint Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study
    Peter Paschka
    Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
    J Clin Oncol 24:3904-11. 2006
  2. pmc Characterization of in vitro and in vivo hypomethylating effects of decitabine in acute myeloid leukemia by a rapid, specific and sensitive LC-MS/MS method
    Zhongfa Liu
    College of Pharmacy, The Ohio State University, Columbus, Ohio 43210, USA
    Nucleic Acids Res 35:e31. 2007
  3. pmc Enrichment-based DNA methylation analysis using next-generation sequencing: sample exclusion, estimating changes in global methylation, and the contribution of replicate lanes
    Michael P Trimarchi
    Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, USA
    BMC Genomics 13:S6. 2012
  4. pmc Clinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patients
    Guido Marcucci
    The Ohio State University, Comprehensive Cancer Center, Biomedical Research Tower 460 W 12th Ave, Columbus, OH 43210, USA
    J Clin Oncol 31:2086-93. 2013
  5. pmc Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia
    Guido Marcucci
    The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA
    J Clin Oncol 30:742-50. 2012
  6. pmc Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study
    Guido Marcucci
    Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
    J Clin Oncol 26:5078-87. 2008
  7. doi request reprint MicroRNA expression in cytogenetically normal acute myeloid leukemia
    Guido Marcucci
    Division of Hematology and Oncology, Comprehensive Cancer Center, Ohio State University, Columbus, OH 43210, USA
    N Engl J Med 358:1919-28. 2008
  8. ncbi request reprint High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study
    Guido Marcucci
    Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
    J Clin Oncol 25:3337-43. 2007
  9. doi request reprint MicroRNA expression in acute myeloid leukemia
    Guido Marcucci
    The Comprehensive Cancer Center, The Ohio State University, A433B Starling Loving Hall, 320 West 10th Avenue, Columbus, OH 43210, USA
    Curr Hematol Malig Rep 4:83-8. 2009
  10. pmc The prognostic and functional role of microRNAs in acute myeloid leukemia
    Guido Marcucci
    Division of Hematology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, 460 West 12th Avenue, Columbus, OH 43210, USA
    Blood 117:1121-9. 2011

Collaborators

Detail Information

Publications121 found, 100 shown here

  1. ncbi request reprint Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study
    Peter Paschka
    Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
    J Clin Oncol 24:3904-11. 2006
    ..To analyze the prognostic impact of mutated KIT (mutKIT) in core-binding factor acute myeloid leukemia (AML) with inv(16)(p13q22) and t(8;21)(q22;q22)...
  2. pmc Characterization of in vitro and in vivo hypomethylating effects of decitabine in acute myeloid leukemia by a rapid, specific and sensitive LC-MS/MS method
    Zhongfa Liu
    College of Pharmacy, The Ohio State University, Columbus, Ohio 43210, USA
    Nucleic Acids Res 35:e31. 2007
    ..Our data support the use of our LC-MS/MS method for clinical pharmacodynamic determination of changes in GDM in vivo...
  3. pmc Enrichment-based DNA methylation analysis using next-generation sequencing: sample exclusion, estimating changes in global methylation, and the contribution of replicate lanes
    Michael P Trimarchi
    Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, USA
    BMC Genomics 13:S6. 2012
    ....
  4. pmc Clinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patients
    Guido Marcucci
    The Ohio State University, Comprehensive Cancer Center, Biomedical Research Tower 460 W 12th Ave, Columbus, OH 43210, USA
    J Clin Oncol 31:2086-93. 2013
    ....
  5. pmc Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia
    Guido Marcucci
    The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA
    J Clin Oncol 30:742-50. 2012
    ....
  6. pmc Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study
    Guido Marcucci
    Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
    J Clin Oncol 26:5078-87. 2008
    ....
  7. doi request reprint MicroRNA expression in cytogenetically normal acute myeloid leukemia
    Guido Marcucci
    Division of Hematology and Oncology, Comprehensive Cancer Center, Ohio State University, Columbus, OH 43210, USA
    N Engl J Med 358:1919-28. 2008
    ..A role of microRNAs in cancer has recently been recognized. However, little is known about the role of microRNAs in acute myeloid leukemia (AML)...
  8. ncbi request reprint High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study
    Guido Marcucci
    Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
    J Clin Oncol 25:3337-43. 2007
    ..To validate ERG overexpression as an adverse predictor and assess its prognostic value in the context of other molecular markers in cytogenetically normal (CN) -acute myeloid leukemia (AML)...
  9. doi request reprint MicroRNA expression in acute myeloid leukemia
    Guido Marcucci
    The Comprehensive Cancer Center, The Ohio State University, A433B Starling Loving Hall, 320 West 10th Avenue, Columbus, OH 43210, USA
    Curr Hematol Malig Rep 4:83-8. 2009
    ..This article reviews recent studies that were focused on the alterations of microRNA expression in AML and their diagnostic and prognostic significance...
  10. pmc The prognostic and functional role of microRNAs in acute myeloid leukemia
    Guido Marcucci
    Division of Hematology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, 460 West 12th Avenue, Columbus, OH 43210, USA
    Blood 117:1121-9. 2011
    ..We review herein results of current studies analyzing changes of microRNA expression in AML and discuss their potential biologic, diagnostic, and prognostic relevance...
  11. doi request reprint MicroRNA expression profiling in acute myeloid and chronic lymphocytic leukaemias
    Guido Marcucci
    Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, 320 West 10th Avenue, Columbus, OH, USA
    Best Pract Res Clin Haematol 22:239-48. 2009
    ..We review herein results of current studies analysing changes of microRNA expression in acute myeloid leukaemia and chronic lymphocytic leukaemia, and discuss their potential biologic, diagnostic and prognostic relevance...
  12. doi request reprint Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications
    Guido Marcucci
    The Ohio State University, Comprehensive Cancer Center, Columbus, OH 43210, USA
    J Clin Oncol 29:475-86. 2011
    ..In this report, we review genetic findings in AML and discuss their clinical implications...
  13. doi request reprint Targeted delivery of antisense oligodeoxynucleotide by transferrin conjugated pH-sensitive lipopolyplex nanoparticles: a novel oligonucleotide-based therapeutic strategy in acute myeloid leukemia
    Yan Jin
    NSF Nanoscale Science and Engineering Center, Division of Pharmaceutics, College of Pharmacy, Department of Chemical and Biomolecular Engineering, The Comprehensive Cancer Center, and Division of Hematology and Oncology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio, USA
    Mol Pharm 7:196-206. 2010
    ..69 nM to 9.05 nM. This study suggests that the combination of pH sensitive LP formulation and Tf mediated targeting is a promising strategy for antisense ODN delivery in leukemia therapy...
  14. pmc MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1
    Ramiro Garzon
    Department of Medicine, Ohio State University, Columbus, 43210, USA
    Blood 113:6411-8. 2009
    ....
  15. pmc RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures
    Jason H Mendler
    The Ohio State University, Comprehensive Cancer Center, 1216 James Cancer Hospital, 300 West 10th Ave, Columbus, OH 43210, USA
    J Clin Oncol 30:3109-18. 2012
    ..To determine the association of RUNX1 mutations with therapeutic outcome in younger and older patients with primary cytogenetically normal acute myeloid leukemia (CN-AML) and with gene/microRNA expression signatures...
  16. pmc Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study
    Heiko Becker
    Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
    J Clin Oncol 28:596-604. 2010
    ....
  17. pmc IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study
    Guido Marcucci
    Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
    J Clin Oncol 28:2348-55. 2010
    ....
  18. pmc Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study
    Heiko Becker
    Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
    Blood 116:788-92. 2010
    ..Our results indicate that WT1mut CN-AML represents a distinct entity with poor treatment response across age groups. This study has been registered at www.clinicaltrials.gov as #NCT00900224...
  19. pmc BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study
    Sebastian Schwind
    Department of Internal Medicine, The Ohio State University, Columbus, OH, USA
    Blood 116:5660-9. 2010
    ....
  20. pmc Modulation of DNA methylation by a sesquiterpene lactone parthenolide
    Zhongfa Liu
    Division of Pharmaceutics, Colleges of Pharmacy, The Ohio State University, Columbus, OH 43210, USA
    J Pharmacol Exp Ther 329:505-14. 2009
    ..Hence, our study established parthenolide as an effective DNA methylation inhibitor, representing a novel prototype for DNMT1 inhibitor discovery and development from natural structural-diversified sesquiterpene lactones...
  21. doi request reprint Delivery of antisense oligodeoxyribonucleotide lipopolyplex nanoparticles assembled by microfluidic hydrodynamic focusing
    Chee Guan Koh
    Department of Chemical and Biomolecular Engineering, The Ohio State University, Columbus, OH 43210, USA
    J Control Release 141:62-9. 2010
    ..MF LP nanoparticles had higher level of Bcl-2 antisense uptake and showed more efficient down-regulation of Bcl-2 protein level than BM LP nanoparticles...
  22. pmc Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study
    Peter Paschka
    Division of Hematology and Oncology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA
    J Clin Oncol 26:4595-602. 2008
    ....
  23. pmc Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia
    Shujun Liu
    Division of Hematology Oncology, The Ohio State University, Columbus, OH 43210, USA
    Cancer Cell 17:333-47. 2010
    ....
  24. ncbi request reprint Chemoresistance to depsipeptide FK228 [(E)-(1S,4S,10S,21R)-7-[(Z)-ethylidene]-4,21-diisopropyl-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8,7,6]-tricos-16-ene-3,6,9,22-pentanone] is mediated by reversible MDR1 induction in human cancer cell lines
    Jim J Xiao
    College of Pharmacy, The Ohio State University, Columbus, OH, USA
    J Pharmacol Exp Ther 314:467-75. 2005
    ..This study reveals a significant role of histone acetylation in MDR1 transcription, which seems to mediate FK228 resistance...
  25. ncbi request reprint Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study
    Guido Marcucci
    Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus OH 43210, USA
    J Clin Oncol 23:9234-42. 2005
    ..To test the prognostic significance of ETS-related gene (ERG) expression in cytogenetically normal primary acute myeloid leukemia (AML)...
  26. pmc The MLL partial tandem duplication: evidence for recessive gain-of-function in acute myeloid leukemia identifies a novel patient subgroup for molecular-targeted therapy
    Susan P Whitman
    Department of Internal Medicine, Division of Hematology Oncology, The Ohio State University, Columbus, OH 43210, USA
    Blood 106:345-52. 2005
    ....
  27. pmc Targeted delivery of microRNA-29b by transferrin-conjugated anionic lipopolyplex nanoparticles: a novel therapeutic strategy in acute myeloid leukemia
    Xiaomeng Huang
    Molecular, Cellular and Developmental Biology, The Ohio State University, Columbus, Ohio 43210, USA
    Clin Cancer Res 19:2355-67. 2013
    ..To overcome these limitations, we developed a novel transferrin-conjugated nanoparticle delivery system for synthetic miR-29b (Tf-NP-miR-29b)...
  28. ncbi request reprint Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study
    Guido Marcucci
    Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, A433B Starling Loving Hall, 320 W 10th Ave, Columbus, OH 43210, USA
    J Clin Oncol 23:5705-17. 2005
    ..Therefore, we sought to determine whether these two cytogenetic groups should also be considered separate entities from a clinical standpoint...
  29. pmc Lenalidomide-mediated enhanced translation of C/EBPα-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia
    Christopher J Hickey
    Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA
    Blood 121:159-69. 2013
    ....
  30. pmc FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study
    Susan P Whitman
    The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA
    Blood 116:3622-6. 2010
    ..FLT3-ITD identifies older CN-AML patients with molecular high risk and is associated with gene- and microRNA-expression signatures that provide biologic insights for novel therapeutic approaches...
  31. pmc ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category
    Klaus H Metzeler
    Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, USA
    Blood 118:6920-9. 2011
    ..This first study of ASXL1 mutations in primary CN-AML demonstrates that ASXL1-mutated older patients, particularly within the ELN Favorable group, have unfavorable outcomes and may be candidates for experimental treatment approaches...
  32. pmc Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: a Cancer and Leukemia Group B study
    Susan P Whitman
    Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43240, USA
    Blood 109:5164-7. 2007
    ..5-7.7 years). Intensive consolidation therapy that included autologous peripheral stem-cell transplantation during CR1 may have contributed to the better outcome of this historically poor-prognosis group of CN-AML patients with MLL-PTD...
  33. pmc DNA hypermethylation and epigenetic silencing of the tumor suppressor gene, SLC5A8, in acute myeloid leukemia with the MLL partial tandem duplication
    Susan P Whitman
    Comprehensive Cancer Center, The Ohio State University, Columbus, USA
    Blood 112:2013-6. 2008
    ..Within the majority of MLL-PTD AML is a mechanism in which DNA hypermethylation silences a TSG that, together with MLL-PTD, can contribute further to aberrant chromatin remodeling and altered gene expression...
  34. pmc TSC-22 contributes to hematopoietic precursor cell proliferation and repopulation and is epigenetically silenced in large granular lymphocyte leukemia
    Jianhua Yu
    Department of Molecular Virology, Immunology, and Medical Genetics, The Ohio State University, Columbus, OH 43210, USA
    Blood 113:5558-67. 2009
    ..Collectively, our data suggest that TSC-22 normally contributes to the regulation of HPC function and is a putative tumor suppressor gene that is hypermethylated and silenced in T or NK LGL leukemia...
  35. pmc Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study
    Christian Langer
    Division of Hematology and Oncology, Comprehensive Cancer Center, The Ohio State University, Suite A434 Starling Loving Hall, 320 W 10th Avenue, Columbus, OH 43210, USA
    J Clin Oncol 27:3198-204. 2009
    ..CONCLUSION MN1 expression independently predicts outcome in CN-AML patients. The MN1 gene- and microRNA-expression signatures suggest biologic features that could be exploited as therapeutic targets...
  36. ncbi request reprint Targeting AML1/ETO-histone deacetylase repressor complex: a novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cells
    Shujun Liu
    Division of Hematology, The Ohio State University, 320 West 10th Avenue, Columbus, OH 43210, USA
    J Pharmacol Exp Ther 321:953-60. 2007
    ....
  37. pmc Identification of novel posttranscriptional targets of the BCR/ABL oncoprotein by ribonomics: requirement of E2F3 for BCR/ABL leukemogenesis
    Anna M Eiring
    Human Cancer Genetics Program, Department of Molecular Virology, Immunology and Medical Genetics and Comprehensive Cancer Center, Ohio State University, Columbus, USA
    Blood 111:816-28. 2008
    ..Thus, the complexity of the mRNA/RBP network, together with the discovery of E2F3 as an hnRNP-A1-regulated factor, outlines the relevant role played by RBPs in posttranscriptional regulation of CML development and progression...
  38. pmc TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study
    Klaus H Metzeler
    The Ohio State University Comprehensive Cancer Center, 1216 James Cancer Hospital, 300 West 10th Ave, Columbus, OH 43210, USA
    J Clin Oncol 29:1373-81. 2011
    ....
  39. pmc Eradicating acute myeloid leukemia in a Mll(PTD/wt):Flt3(ITD/wt) murine model: a path to novel therapeutic approaches for human disease
    Kelsie M Bernot
    The Ohio State University Comprehensive Cancer Center and The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, OH
    Blood 122:3778-83. 2013
    ..Taken together, these data support that liposomal bortezomib, as a single agent, eradicates Mll(PTD/wt):Flt3(ITD/wt) AML in mouse and may represent a powerful and potentially curative approach to high-risk human disease. ..
  40. ncbi request reprint Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematologic malignancies
    Mehdi Hamadani
    Division of Hematology Oncology, Blood and Marrow Transplantation Section, and Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio 43210, USA
    Biol Blood Marrow Transplant 15:1422-30. 2009
    ....
  41. pmc High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) st
    Christian Langer
    Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
    Blood 111:5371-9. 2008
    ..We conclude that high BAALC expression is an independent adverse prognostic factor and is associated with a specific gene-expression profile...
  42. pmc Clinical outcome and gene- and microRNA-expression profiling according to the Wilms tumor 1 (WT1) single nucleotide polymorphism rs16754 in adult de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study
    Heiko Becker
    Division of Hematology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
    Haematologica 96:1488-95. 2011
    ..To validate this finding, we investigated pretreatment features and outcome associated with rs16754 in a large cohort of patients with cytogenetically normal acute myeloid leukemia...
  43. pmc The Mll partial tandem duplication: differential, tissue-specific activity in the presence or absence of the wild-type allele
    Adrienne M Dorrance
    Department of Internal Medicine, Division of Hematology and Oncology, James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, USA
    Blood 112:2508-11. 2008
    ..The differences between these 2 genotypes suggest that in select tissues the Mll-PTD requires cooperation with the Mll-WT in the genesis of the observed abnormality...
  44. pmc Independent confirmation of a prognostic gene-expression signature in adult acute myeloid leukemia with a normal karyotype: a Cancer and Leukemia Group B study
    Michael D Radmacher
    Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Suite A455 Starling Loving Hall, 320 West Tenth Ave, Columbus, OH 43210, USA
    Blood 108:1677-83. 2006
    ..Our analysis confirms the applicability of the gene-expression profiling strategy for outcome prediction in cytogenetically normal AML...
  45. ncbi request reprint BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study
    Claudia D Baldus
    The Ohio State University, Starling Loving Hall, 320 West 10th Ave, Columbus, OH 43210, USA
    Blood 102:1613-8. 2003
    ..7, 2.6, and 2.2. We conclude that high BAALC expression predicts an adverse prognosis and may define an important risk factor in AML with normal cytogenetics...
  46. ncbi request reprint Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity
    Guido Marcucci
    Division of Hematology Oncology, The Comprehensive Cancer Center, The Ohio State University, 433A Starling Loving Hall, 320 West 10th Ave, Columbus, OH 43210, USA
    J Clin Oncol 23:3404-11. 2005
    ..Herein, we investigated the feasibility of this approach in untreated elderly AML patients by administering oblimersen sodium (G3139), an 18-mer phosphorothioate antisense to Bcl-2, during induction and consolidation treatments...
  47. pmc MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia
    Ramiro Garzon
    Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, Ohio State University, Columbus, OH 43210, USA
    Blood 111:3183-9. 2008
    ..03; and miR-199a, P = .001, Cox regression). In conclusion, miRNA expression in AML is closely associated with cytogenetics and FLT3-ITD mutations. A small subset of miRNAs is correlated with survival...
  48. pmc Silvestrol exhibits significant in vivo and in vitro antileukemic activities and inhibits FLT3 and miR-155 expressions in acute myeloid leukemia
    Houda Alachkar
    Division of Hematology, Department of Medicine, The Ohio State University, Columbus, OH, USA
    J Hematol Oncol 6:21. 2013
    ..We examined here the preclinical activity of silvestrol in FLT3-ITD and FLT3 wild-type (wt) AML...
  49. pmc MicroRNA 29b functions in acute myeloid leukemia
    Ramiro Garzon
    Division of Hematology and Oncology, Immunology and Medical Genetics, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
    Blood 114:5331-41. 2009
    ..Together, the data support a tumor suppressor role for miR-29 and provide a rationale for the use of synthetic miR-29b oligonucleotides as a novel strategy to improve treatment response in AML...
  50. pmc FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia
    Paolo Neviani
    Human Cancer Genetics Program, Department of Molecular Virology, Immunology and Medical Genetics, The Ohio State University, Columbus, Ohio, USA
    J Clin Invest 117:2408-21. 2007
    ..Altogether, these results highlight the therapeutic relevance of rescuing PP2A tumor suppressor activity in Ph1 leukemias and strongly support the introduction of the PP2A activator FTY720 in the treatment of CML-BC and Ph1 ALL patients...
  51. pmc Disulfide-linked liposomes: effective delivery vehicle for Bcl-2 antisense oligodeoxyribonucleotide G3139
    Wanlop Weecharangsan
    College of Pharmacy, The Ohio State University, 542 LM Parks Hall, 500 W 12th Ave, Columbus, OH 43210, USA
    Anticancer Res 30:31-7. 2010
    ..Disulfide-linked oligodeoxyribonucleotide (ODN) liposomes were formulated and evaluated for the delivery of antisense ODN G3139 in KB human oral carcinoma cells...
  52. doi request reprint Epigenetics meets genetics in acute myeloid leukemia: clinical impact of a novel seven-gene score
    Guido Marcucci
    Guido Marcucci, Pearlly Yan, Kati Maharry, David Frankhouser, Deedra Nicolet, Klaus H Metzeler, Jessica Kohlschmidt, Krzysztof Mrózek, Yue Zhong Wu, Donna Bucci, John P Curfman, Susan P Whitman, Ann Kathrin Eisfeld, Jason H Mendler, Sebastian Schwind, Heiko Becker, John C Byrd, Ramiro Garzon, Michael A Caligiuri, Stefano Volinia, and Clara D Bloomfield, The Ohio State University Comprehensive Cancer Center Ralf Bundschuh, The Ohio State University, Columbus, OH Kati Maharry, Deedra Nicolet, and Jessica Kohlschmidt, Alliance for Clinical Trials in Oncology Statistics and Data Center, Mayo Clinic, Rochester, MN Andrew J Carroll, University of Alabama at Birmingham, Birmingham, AL Maria R Baer, Czech Republic
    J Clin Oncol 32:548-56. 2014
    ..However, epigenetic changes, including DNA methylation, deregulate gene expression and may also have prognostic impact. We evaluated the clinical relevance of integrating DNA methylation and genetic information in AML...
  53. ncbi request reprint A specific picomolar hybridization-based ELISA assay for the determination of phosphorothioate oligonucleotides in plasma and cellular matrices
    Xiaohui Wei
    Division of Pharmaceutics, College of Pharmacy, The Ohio State University, Columbus, Ohio 43210, USA
    Pharm Res 23:1251-64. 2006
    ..To develop and validate an ultrasensitive and specific hybridization-based enzyme-linked immunosorbent assay method for quantification of two phosphorothioate oligonucleotides (PS ODNs) (G3139 and GTI-2040) in biological fluids...
  54. ncbi request reprint Cellular uptake and intracellular levels of the bcl-2 antisense g3139 in cultured cells and treated patients with acute myeloid leukemia
    Guowei Dai
    Division of Pharmaceutics, College of Medicine and Public Health, Ohio State University, Columbus, Ohio 43210, USA
    Clin Cancer Res 11:2998-3008. 2005
    ..This study aimed to assess whether detectable intracellular concentrations of G3139 are achievable in vivo and how these relate to Bcl-2 down-regulation...
  55. pmc miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemia
    Ann Kathrin Eisfeld
    The Ohio State University Comprehensive Cancer Center, 300 West 10th Ave, Columbus, OH 43210, USA
    Blood 120:249-58. 2012
    ..The combination of both markers identified a patient subset with the poorest outcome. This interplay between an intronic miR and its host may have important biologic implications...
  56. pmc Phase I study of GTI-2040, an antisense to ribonucleotide reductase, in combination with high-dose cytarabine in patients with acute myeloid leukemia
    Rebecca B Klisovic
    Division of Hematology and Oncology, The Ohio State University, Columbus, Ohio, USA
    Clin Cancer Res 14:3889-95. 2008
    ....
  57. pmc Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine
    William Blum
    Division of Hematology and Oncology, Department of Medicine, and Center for Biostatistics, Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA
    Proc Natl Acad Sci U S A 107:7473-8. 2010
    ..Levels of miR-29b should be validated as a predictive factor for stratification of older AML patients to decitabine treatment...
  58. pmc Mll partial tandem duplication induces aberrant Hox expression in vivo via specific epigenetic alterations
    Adrienne M Dorrance
    Department of Internal Medicine, Division of Hematology and Oncology, The Ohio State University, Columbus, Ohio 43220, USA
    J Clin Invest 116:2707-16. 2006
    ....
  59. pmc Biochemical modulation of aracytidine (Ara-C) effects by GTI-2040, a ribonucleotide reductase inhibitor, in K562 human leukemia cells
    Ping Chen
    College of Pharmacy, The Ohio State University, Columbus, Ohio 43210, USA
    AAPS J 13:131-40. 2011
    ..This finding provides a laboratory justification for the current phase I/II evaluation of GTI-2040 in combination with Ara-C in patients with acute myeloid leukemia...
  60. ncbi request reprint 5-Aza-2'-deoxycytidine and depsipeptide synergistically induce expression of BIK (BCL2-interacting killer)
    Zunyan Dai
    Program of Pharmacogenomics, Department of Pharmacology, The Ohio State University, Columbus, OH, USA
    Biochem Biophys Res Commun 351:455-61. 2006
    ..In summary, synergistic upregulation of pro-apoptotic BIK-previously shown to suppress tumor growth-appears to play a critical role in anticancer effects of 5-aza-2'-deoxycytidine plus depsipeptide...
  61. pmc Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia
    Krzysztof Mrozek
    The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210 1228, USA
    J Clin Oncol 30:4515-23. 2012
    ..To evaluate the prognostic significance of the international European LeukemiaNet (ELN) guidelines for reporting genetic alterations in acute myeloid leukemia (AML)...
  62. pmc miR-155 targets histone deacetylase 4 (HDAC4) and impairs transcriptional activity of B-cell lymphoma 6 (BCL6) in the Eμ-miR-155 transgenic mouse model
    Sukhinder K Sandhu
    Department of Molecular Virology, Ohio State University Medical Center, Columbus, OH 43210, USA
    Proc Natl Acad Sci U S A 109:20047-52. 2012
    ..Hence this study provides a better understanding of how miR-155 causes disruption of the BCL6 transcriptional machinery that leads to up-regulation of the survival and proliferation genes in miR-155-induced leukemias...
  63. pmc A LC-MS/MS method for the analysis of intracellular nucleoside triphosphate levels
    Ping Chen
    College of Pharmacy, The Ohio State University, 500 W 12th Avenue, Columbus, OH 43210, USA
    Pharm Res 26:1504-15. 2009
    ..To simultaneously quantify intracellular nucleoside triphosphate (NTP) and deoxynucleoside triphosphate (dNTP) pools and to assess their changes produced by interfering with ribonucleotide reductase (RNR) expression in leukemia cells...
  64. pmc CD94 surface density identifies a functional intermediary between the CD56bright and CD56dim human NK-cell subsets
    Jianhua Yu
    Department of Molecular Virology, Immunology, and Medical Genetics, Ohio State University, Columbus, OH 43210, USA
    Blood 115:274-81. 2010
    ..This supports the notion that, in vivo, human CD56(bright) NK cells progress through a continuum of differentiation that ends with a CD94(low)CD56(dim) phenotype...
  65. pmc Transferrin receptor-targeted lipid nanoparticles for delivery of an antisense oligodeoxyribonucleotide against Bcl-2
    Xiaojuan Yang
    Division of Pharmaceutics, The Ohio State University, Columbus, Ohio 43210, USA
    Mol Pharm 6:221-30. 2009
    ..Tf-LN-mediated delivery combined with TfR up-regulation by deferoxamine appears to be a potentially promising strategy for enhancing the delivery efficiency and therapeutic efficacy of antisense oligonucleotides...
  66. pmc Histone H4 acetylation dynamics determined by stable isotope labeling with amino acids in cell culture and mass spectrometry
    Xiaodan Su
    Department of Chemistry, The Ohio State University, Columbus, OH 43210, USA
    Anal Biochem 363:22-34. 2007
    ....
  67. pmc A novel liposomal formulation of flavopiridol
    Xiaojuan Yang
    Division of Pharmaceutics, College of Pharmacy, The Ohio State University, Columbus, OH 43210, USA
    Int J Pharm 365:170-4. 2009
    ..Further preclinical studies are warranted to define the toxicity and therapeutic efficacy of this novel formulation...
  68. pmc Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemia
    Sebastian Schwind
    Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
    Blood 118:4188-98. 2011
    ..We conclude that low MN1 expression confers better prognosis in older CN-AML patients and may refine the European LeukemiaNet classification. Biologic features associated with MN1 expression may help identify new treatment targets...
  69. pmc Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias
    William Blum
    Division of Hematology and Oncology and the Comprehensive Cancer Center, Department of Medicine, The Ohio State University, B310 Starling Loving Hall, 320 West 10 Avenue, Columbus, OH 43210, USA
    Haematologica 95:1098-105. 2010
    ....
  70. pmc Targeted nanoparticle delivery overcomes off-target immunostimulatory effects of oligonucleotides and improves therapeutic efficacy in chronic lymphocytic leukemia
    Bo Yu
    Department of Chemical and Biomolecular Engineering, The Ohio State University, Columbus, OH, USA
    Blood 121:136-47. 2013
    ..The broader implications of similar approaches in overcoming immunostimulatory properties of RNA-directed therapeutics in hematologic malignancies are also discussed...
  71. pmc Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia
    William Blum
    Division of Hematology, Department of Medicine, The Ohio State University Comprehensive Cancer Center, B310 Starling Loving Hall, Columbus, OH 43210, USA
    Blood 119:6025-31. 2012
    ..This study demonstrates the feasibility and preliminary clinical activity of decitabine plus bortezomib in AML and identifies FLT3 as a novel pharmacodynamic end point for future trials...
  72. pmc RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemia
    Josephine Aimiuwu
    Division of Pharmaceutics, College of Pharmacy, The Ohio State University, Columbus, OH 43210, USA
    Blood 119:5229-38. 2012
    ..In conclusion, we identify RRM2 as a novel molecular target of 5-azaC in AML. Our findings provide a basis for its more widespread clinical use either alone or in combination...
  73. pmc Efficient delivery of antisense oligodeoxyribonucleotide g3139 by human serum albumin-coated liposomes
    Wanlop Weecharangsan
    Division of Pharmaceutics, College of Pharmacy, The Ohio State University, Columbus, Ohio 43210, USA
    Mol Pharm 6:1848-55. 2009
    ..HSA-coated liposomes are effective delivery vehicles for antisense ODN...
  74. pmc Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF-kappaB-dependent DNA methyltransferase activity in acute myeloid leukemia
    Shujun Liu
    Division of Hematology Oncology, The Ohio State University, Columbus, OH 43210, USA
    Blood 111:2364-73. 2008
    ..Our results unveil the Sp1/NF-kappaB pathway as a modulator of DNA methyltransferase activity in human cancer and identify bortezomib as a novel epigenetic-targeting drug...
  75. pmc Phase I trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: dose-limiting myelosuppression without evidence of DNA hypomethylation
    Kristie A Blum
    Division of Hematology Oncology, Department of Internal Medicine, The Arthur G James Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
    Br J Haematol 150:189-95. 2010
    ..In conclusion, dose-limiting myelosuppression and infectious complications prevented dose escalation of decitabine to levels associated with changes in global methylation or gene re-expression in CLL and NHL...
  76. ncbi request reprint Interplay of RUNX1/MTG8 and DNA methyltransferase 1 in acute myeloid leukemia
    Shujun Liu
    Divisions of Hematology Oncology, Department of Internal Medicine and the Comprehensive Cancer Center, Ohio State University, Columbus, Ohio, USA
    Cancer Res 65:1277-84. 2005
    ..These results suggest a novel mechanism for gene silencing mediated by RUNX1/MTG8 and support the combination of HDAC and DNMT inhibitors as a novel therapeutic approach for t(8;21) AML...
  77. pmc Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells
    Rosa Lapalombella
    Division of Hematology Oncology, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, USA
    Blood 112:5180-9. 2008
    ..In addition, they suggest that lenalidomide therapy might be useful to enhance targeted delivery of RNAi-based therapies using CD20 immunoliposomes in B-cell malignancies...
  78. doi request reprint Epigenetic modification of CCAAT/enhancer binding protein alpha expression in acute myeloid leukemia
    Björn Hackanson
    Department of Molecular Virology, Immunology and Medical Genetics, Division of Human Cancer Genetics, College of Pharmacy, Ohio State University, Columbus, Ohio, USA
    Cancer Res 68:3142-51. 2008
    ..Our results indicate that epigenetic alterations of C/EBP alpha are a frequent event in AML and that epigenetic treatment can result in down-regulation of a key hematopoietic transcription factor...
  79. ncbi request reprint Allogeneic stem cell transplantation for patients with relapsed chemorefractory aggressive non-hodgkin lymphomas
    Mehdi Hamadani
    Hematology and Oncology, Arthur G James Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio 43210, USA
    Biol Blood Marrow Transplant 15:547-53. 2009
    ..Given the outcomes seen here in the setting of PD, such patients should proceed with transplant only in the setting of investigational therapy...
  80. ncbi request reprint Depsipeptide inhibits migration of primary and metastatic uveal melanoma cell lines in vitro: a potential strategy for uveal melanoma
    Dino D Klisovic
    William H Havener Eye Center, Columbus, OH, USA
    Melanoma Res 15:147-53. 2005
    ..Our data suggest that this inhibition is mediated by the downregulation of MMPs and the upregulation of TIMPs. DP may be a valuable adjunctive treatment modality for primary and metastatic UM in humans...
  81. ncbi request reprint Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia
    William Blum
    Department of Medicine, Division of Hematology and Oncology, The Ohio State University, Columbus, OH 43210, USA
    J Clin Oncol 25:3884-91. 2007
    ..To determine an optimal biologic dose (OBD) of decitabine as a single agent and then the maximum-tolerated dose (MTD) of valproic acid (VA) combined with decitabine in acute myeloid leukemia (AML)...
  82. pmc FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications
    Susan P Whitman
    Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio 43240, USA
    Blood 111:1552-9. 2008
    ....
  83. pmc Epigenetic changes during disease progression in a murine model of human chronic lymphocytic leukemia
    Shih Shih Chen
    Department of Molecular Virology, Immunology, and Medical Genetics, Human Cancer Genetics Program, Comprehensive Cancer Center, Ohio State University, Columbus, OH 43210, USA
    Proc Natl Acad Sci U S A 106:13433-8. 2009
    ..These results provide strong rationale for the development of strategies to target NF-kappaB components in CLL and potentially other B-cell malignancies...
  84. pmc Dose escalation of lenalidomide in relapsed or refractory acute leukemias
    William Blum
    Division of Hematology, The Ohio State University and The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA
    J Clin Oncol 28:4919-25. 2010
    ..Lenalidomide is effective in myeloma and low-risk myelodysplastic syndromes with deletion 5q. We report results of a phase I dose-escalation trial of lenalidomide in relapsed or refractory acute leukemia...
  85. ncbi request reprint Pro- and antiinflammatory cytokine signaling: reciprocal antagonism regulates interferon-gamma production by human natural killer cells
    Jianhua Yu
    Department of Molecular Virology, Immunology, and Medical Genetics, The Ohio State University College of Medicine and School of Public Health, Columbus, Ohio 43210, USA
    Immunity 24:575-90. 2006
    ..Collectively, our data suggest that pro- and antiinflammatory cytokine signaling reciprocally antagonize each other in an effort to prevail in the regulation of NK cell IFN-gamma production...
  86. pmc Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study
    Sebastian Schwind
    The Ohio State University, Comprehensive Cancer Center, Biomedical Research Tower, 460 W 12th Ave, Columbus, OH 43210, USA
    J Clin Oncol 28:5257-64. 2010
    ....
  87. pmc MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B
    Muller Fabbri
    Department of Molecular Virology, Immunology, and Medical Genetics, Comprehensive Cancer Center, and College of Pharmacy, Ohio State University, Columbus, OH 43210, USA
    Proc Natl Acad Sci U S A 104:15805-10. 2007
    ..These findings support a role of miR-29s in epigenetic normalization of NSCLC, providing a rationale for the development of miRNA-based strategies for the treatment of lung cancer...
  88. ncbi request reprint Molecular heterogeneity and prognostic biomarkers in adults with acute myeloid leukemia and normal cytogenetics
    Guido Marcucci
    Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio 43210, USA
    Curr Opin Hematol 12:68-75. 2005
    ..This article critically reviews the recent literature that addresses the molecular heterogeneity of this group of patients and how this relates to prognostic stratification and novel therapeutic approaches...
  89. ncbi request reprint Depsipeptide (FR901228) induces histone acetylation and inhibition of histone deacetylase in chronic lymphocytic leukemia cells concurrent with activation of caspase 8-mediated apoptosis and down-regulation of c-FLIP protein
    Jennifer L Aron
    Department of Internal Medicine, The Division of Hematology Oncology, The Ohio State University, Columbus, USA
    Blood 102:652-8. 2003
    ..These data suggest use of histone H3 and H4 acetylation, inhibition of histone deacetylase, and down-regulation of FLIP as pharmacodynamic end points for further evaluation of this drug in patients...
  90. ncbi request reprint Transcriptional control of human T-BET expression: the role of Sp1
    Jianhua Yu
    Division of Hematology Oncology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA
    Eur J Immunol 37:2549-61. 2007
    ....
  91. ncbi request reprint Hyperglycemia in patients with acute myeloid leukemia is associated with increased hospital mortality
    Naeem A Ali
    Division of Pulmonary, Critical Care, Allergy and Sleep Medicine, Ohio State University, Columbus, Ohio 43210, USA
    Cancer 110:96-102. 2007
    ..The authors hypothesized that hyperglycemia may be associated with adverse outcomes in patients with acute myeloid leukemia (AML) and sought to determine whether this association exists in this population...
  92. ncbi request reprint Global assessment of promoter methylation in a mouse model of cancer identifies ID4 as a putative tumor-suppressor gene in human leukemia
    Li Yu
    Internal Medicine, Division of Hematology Oncology, The Ohio State University, Columbus, Ohio 43210, USA
    Nat Genet 37:265-74. 2005
    ..We also identified Idb4 as a putative tumor-suppressor gene that is methylated in most mouse and human leukemias but in only a minority of other human cancers...
  93. doi request reprint Targeting microRNAs in cancer: rationale, strategies and challenges
    Ramiro Garzon
    Division of Haematology and Oncology, Department of Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio 43221, USA
    Nat Rev Drug Discov 9:775-89. 2010
    ..In this Review, we describe the role of miRNAs in tumorigenesis and critically discuss the rationale, the strategies and the challenges for the therapeutic targeting of miRNAs in cancer...
  94. doi request reprint Molecular signatures in acute myeloid leukemia
    Krzysztof Mrozek
    Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, 43210 1228, USA
    Curr Opin Hematol 16:64-9. 2009
    ..In this article, we review the results of recent studies of AML that used microarray-based genome-wide gene-expression and microRNA-expression profiling...
  95. ncbi request reprint Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia
    Guido Marcucci
    Division of Hematology Oncology, Department of Medicine, and the Comprehensive Cancer Center, Ohio State University, Columbus 43210, USA
    Blood 101:425-32. 2003
    ..The encouraging clinical and laboratory results justify the current plans for a phase 3 study in previously untreated high-risk AML (ie, age at least 60 years)...
  96. doi request reprint New approaches in acute myeloid leukemia
    William Blum
    Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
    Best Pract Res Clin Haematol 21:29-41. 2008
    ..The following is an outline of several key areas of ongoing AML research...
  97. pmc Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?
    Krzysztof Mrozek
    Department of Internal Medicine, The Arthur G James Cancer Hospital and Richard J Solove Research Institute, Room 1248B, The Ohio State University, 300 West Tenth Ave, Columbus, OH 43210 1228, USA
    Blood 109:431-48. 2007
    ..In this report, we review prognostic genetic findings in karyotypically normal AML and discuss their clinical implications...
  98. ncbi request reprint Targeting epigenetic changes in acute myeloid leukemia
    William Blum
    The Ohio State University, Columbus, Ohio, USA
    Clin Adv Hematol Oncol 3:855-65, 882. 2005
    ..In this review, we focus on the clinical applicability of epigenetic targeting in the treatment of patients with AML...
  99. pmc Advances in molecular genetics and treatment of core-binding factor acute myeloid leukemia
    Krzysztof Mrozek
    Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio 43210 1228, USA
    Curr Opin Oncol 20:711-8. 2008
    ....
  100. ncbi request reprint Long-term outcome of Hodgkin disease patients following high-dose busulfan, etoposide, cyclophosphamide, and autologous stem cell transplantation
    Navin Wadehra
    Division of Hematology and Oncology, The Ohio State University Hospitals, Columbus, Ohio, USA
    Biol Blood Marrow Transplant 12:1343-9. 2006
    ..This novel Bu regimen is comparable to other radiation-free preparative regimens in its effectiveness in the control of HD and with a low-risk of early treatment-related mortality...
  101. pmc NKp46 identifies an NKT cell subset susceptible to leukemic transformation in mouse and human
    Jianhua Yu
    Department of Molecular Virology, Immunology, and Medical Genetics, The Ohio State University, Columbus, Ohio, USA
    J Clin Invest 121:1456-70. 2011
    ..Thus, IL-15 signaling and NKp46 may be useful targets in the treatment of patients with T-LGL or NKT leukemia...

Research Grants6

  1. PHARMACOLOGICAL MODULATION OF EPIGENETIC CHANGES IN AML
    Guido Marcucci; Fiscal Year: 2004
    ..e., valproic acid); 2) to perform pharmacokinetic and pharmacodynamic studies of these agents that will allow correlations of drug plasma levels, chromatin changes and gene re-expression with toxicity and disease response. ..
  2. PHARMACOLOGICAL MODULATION OF EPIGENETIC CHANTGES IN AML
    Guido Marcucci; Fiscal Year: 2005
    ..e., valproic acid); 2) to perform pharmacokinetic and pharmacodynamic studies of these agents that will allow correlations of drug plasma levels, chromatin changes and gene re-expression with toxicity and disease response. ..
  3. PHARMACOLOGICAL MODULATION OF EPIGENETIC CHANTGES IN AML
    Guido Marcucci; Fiscal Year: 2006
    ..e., valproic acid); 2) to perform pharmacokinetic and pharmacodynamic studies of these agents that will allow correlations of drug plasma levels, chromatin changes and gene re-expression with toxicity and disease response. ..
  4. Phamacological modulation of epigenetic changes in AML
    Guido Marcucci; Fiscal Year: 2009
    ..This knowledge will be used to design more effective treatment for AML . ..
  5. Phamacological modulation of epigenetic changes in AML
    Guido Marcucci; Fiscal Year: 2010
    ..This knowledge will be used to design more effective treatment for AML . ..